arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

IN8BIO, INC.

INAB
$1.10 ▼ -0.04 (-3.91%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
17 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

IN8BIO, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $21.4M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -20.6% ↘
FCF / Share $-0.19 ↗
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-5.09M
↑ +8.3% —
FCF / Share Free cash flow per share
$-0.19
↑ +24.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
12
Cash Quality ↓
46

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters